1,510
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma

, , ORCID Icon, ORCID Icon, , , , , , , , , , , & show all
Pages 2225-2235 | Received 21 Aug 2023, Accepted 08 Sep 2023, Published online: 23 Sep 2023